ATE170082T1 - Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen - Google Patents
Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilenInfo
- Publication number
- ATE170082T1 ATE170082T1 AT95117465T AT95117465T ATE170082T1 AT E170082 T1 ATE170082 T1 AT E170082T1 AT 95117465 T AT95117465 T AT 95117465T AT 95117465 T AT95117465 T AT 95117465T AT E170082 T1 ATE170082 T1 AT E170082T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- growth
- inhibiting
- cells
- leukemic cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33760594A | 1994-11-10 | 1994-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE170082T1 true ATE170082T1 (de) | 1998-09-15 |
Family
ID=23321225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95117465T ATE170082T1 (de) | 1994-11-10 | 1995-11-07 | Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0711565B1 (de) |
| AT (1) | ATE170082T1 (de) |
| DE (1) | DE69504278T2 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP2110138A1 (de) | 1999-08-27 | 2009-10-21 | Genentech, Inc. | Dosierungen zur Behandlung von Anti-erbB2-Antikörpern |
| CA2383615A1 (en) * | 1999-09-22 | 2001-03-29 | Corixa Corporation | Methods for diagnosis and therapy of hematological and virus-associated malignancies |
| WO2001089566A1 (en) | 2000-05-19 | 2001-11-29 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| AU2001283360A1 (en) * | 2000-08-14 | 2002-02-25 | Corixa Corporation | Methods for diagnosis and therapy of hematological and virus-associated malignancies |
| EP3698807A1 (de) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixe dosierung von her-antikörpern |
| RS53128B (sr) | 2005-02-23 | 2014-06-30 | Genentech Inc. | Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba |
| MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| WO2008154249A2 (en) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| JP2012507299A (ja) * | 2008-10-31 | 2012-03-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Light標的分子およびその使用 |
| KR20150036824A (ko) | 2009-03-20 | 2015-04-07 | 제넨테크, 인크. | 이중특이적 항-her 항체 |
| US20120121586A1 (en) | 2009-05-29 | 2012-05-17 | Astrid Kiermaier | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| ES2519348T3 (es) | 2010-02-18 | 2014-11-06 | Genentech, Inc. | Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
| EP2655413B1 (de) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung |
| BR112014003431A2 (pt) | 2011-08-17 | 2017-06-13 | Genentech Inc | anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor |
| WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
| AU2012346540C1 (en) | 2011-11-30 | 2019-07-04 | Genentech, Inc. | ErbB3 mutations in cancer |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| WO2013148315A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| RU2692773C2 (ru) | 2012-11-30 | 2019-06-27 | Ф.Хоффманн-Ля Рош Аг | Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1 |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
-
1995
- 1995-11-07 EP EP95117465A patent/EP0711565B1/de not_active Expired - Lifetime
- 1995-11-07 AT AT95117465T patent/ATE170082T1/de not_active IP Right Cessation
- 1995-11-07 DE DE69504278T patent/DE69504278T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69504278D1 (de) | 1998-10-01 |
| EP0711565A1 (de) | 1996-05-15 |
| DE69504278T2 (de) | 1999-05-06 |
| EP0711565B1 (de) | 1998-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69504278D1 (de) | Verfahren zur Wachstumshemmung von Leukämischen Zellen durch HER-2-Protein-Zeilen | |
| DE60330390D1 (de) | G-csf zur behandlung von amyotropher lateralsklerose | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| DE69508192D1 (de) | Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen | |
| ATE402698T1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
| DE69809898D1 (de) | Zusammensetzung und verfahren zur behandlung von pflanzen mit exogenen chemikalien | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| TW200502385A (en) | Modulation of forkhead box o1a expression | |
| DE69523074D1 (de) | Verfahren zur behandlung von implantierbaren biologischen geweben zur verringerung von verkalkung | |
| ATE465261T1 (de) | Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken | |
| ATE526980T1 (de) | Zusammensetzungen und verfahren zur heilung von nervengeweben | |
| DE69622989D1 (de) | Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten | |
| DE60015791D1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| DE60111620D1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
| DE69619187D1 (de) | Verfahren zur behandlung von motorischen defiziten | |
| ATE331799T1 (de) | Verfahren zur inhibierung der transkription von genen | |
| ATE203271T1 (de) | Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung | |
| ATE251462T1 (de) | Verfahren zur behandlung von narbengewebe | |
| ATE288498T1 (de) | Methoden zur inhibierung von helicobacter pylori | |
| ATE203162T1 (de) | Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one | |
| DE60034110D1 (de) | Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien | |
| ATE438859T1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
| ATE325812T1 (de) | Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors | |
| ATE311901T1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
| ATE320263T1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |